Logo

NVNO

enVVeno Medical Corporation

NVNO

enVVeno Medical Corporation • NASDAQ
$0.38 ▲ 12.79% (+0.04)
Market Cap $7.75 M
52w High $5.62
52w Low $0.30
Dividend Yield 0%
P/E -0.36
Volume 448.44K
Outstanding Shares 20.22M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $4.763M ▼ $-4.539M ▲ 0% $-0.23 ▲ $-4.419M ▲
Q2-2025 $0 $6.919M ▲ $-6.694M ▼ 0% $-0.33 ▼ $-6.564M ▼
Q1-2025 $0 $4.832M ▼ $-4.503M ▲ 0% $-0.22 ▲ $-4.381M ▲
Q4-2024 $0 $6.577M ▲ $-6.229M ▼ 0% $-0.31 ▲ $-6.107M ▼
Q3-2024 $0 $6.041M $-5.642M 0% $-0.35 $-5.513M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $30.952M ▼ $32.352M ▼ $2.905M ▼ $29.447M ▼
Q2-2025 $35.142M ▼ $36.577M ▼ $3.52M ▲ $33.057M ▼
Q1-2025 $38.941M ▼ $40.577M ▼ $2.27M ▼ $38.307M ▼
Q4-2024 $43.153M ▼ $44.954M ▼ $2.795M ▼ $42.159M ▼
Q3-2024 $48.379M $50.39M $3.02M $47.37M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.414M ▲ $-4.392M ▼ $3.651M ▲ $241K ▲ $-500K ▲ $-4.392M ▼
Q2-2025 $-8.819M ▼ $-3.715M ▲ $2.822M ▼ $0 $-893K ▼ $-3.72M ▲
Q1-2025 $-4.503M ▲ $-4.018M ▲ $5.201M ▲ $0 $1.183M ▲ $-4.018M ▲
Q4-2024 $-6.229M ▼ $-5.105M ▼ $-11.056M ▼ $0 ▼ $-16.161M ▼ $-5.109M ▼
Q3-2024 $-5.642M $-4.276M $6.22M $13.591M $15.535M $-4.285M

Revenue by Products

Product Q3-2018Q4-2018Q2-2019Q3-2019
Royalty Income
Royalty Income
 $0 ▲$0 ▲$0 ▲$0 ▲
Contract Research Related Party
Contract Research Related Party
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement enVVeno is still a pre‑revenue, clinical‑stage company, so it has not generated product sales in recent years. Its costs relate mainly to research, clinical trials, and overhead, which result in consistent operating and net losses. Those losses have been relatively steady over time rather than sharply accelerating, suggesting a controlled burn rate but no clear path yet to break-even. The negative earnings per share reflect this ongoing investment phase and the small company scale, not any underlying revenue weakness, since there is no commercial business yet.

Balance Sheet

Balance Sheet The balance sheet is simple and relatively clean. The company carries no financial debt, and its assets are funded almost entirely by shareholder equity, which limits balance‑sheet risk but implies reliance on equity capital. Reported cash balances fluctuate, but management commentary indicates enough liquidity to fund operations for several years, assuming plans and spending stay on track. Overall, it looks like a small but straightforward balance sheet, with future strength depending heavily on continued access to capital and progress toward commercialization.

Cash Flow

Cash Flow Cash flows are negative, driven by operating outflows to fund research and clinical development. The burn appears modest and fairly stable, with little to no spending on heavy equipment or facilities, which keeps capital needs somewhat contained. Free cash flow is therefore negative but predictable, fitting the profile of a focused, early‑stage medtech company. Over time, the company will need either partnerships, new financing, or product revenue to support this ongoing cash usage.

Competitive Edge

Competitive Edge enVVeno is targeting a very specific and underserved problem: chronic venous insufficiency driven by faulty venous valves. Its key edge is being one of the few companies working on actual valve replacement rather than just symptom management or vein closure, which gives it a differentiated position. Intellectual property around its valve designs and delivery systems, plus its early experience in this niche, create some protection against new entrants. That said, it is a small player operating in a space where large device companies are active in adjacent treatments, so execution, clinical proof, and regulatory success will be critical to defend and expand its niche.

Innovation and R&D

Innovation and R&D The company’s value story is almost entirely about innovation. First, it developed the VenoValve, a surgical bioprosthetic valve that showed encouraging clinical signals but ran into a regulatory setback in the United States. In response, enVVeno is pivoting emphasis to enVVe, a next‑generation, minimally invasive transcatheter valve that could be more attractive to physicians and patients if it proves safe and effective. This pivot shows flexibility but also concentrates risk in a pipeline that is still early in human testing, making future outcomes highly dependent on upcoming trials and regulatory reviews.

Summary

enVVeno is a classic early‑stage medical device developer: no revenue yet, steady operating losses, and a balance sheet funded by equity rather than debt. Financially, the story is about managing a controlled cash burn while advancing a small number of high‑impact clinical programs. Strategically, the company has carved out a focused niche in venous valve replacement with differentiated technology and some first‑mover advantages. The recent regulatory setback for its surgical product raises risk but has prompted a shift toward a potentially more scalable, less invasive transcatheter platform. Overall, the company’s prospects hinge on successful clinical validation and regulatory clearance of enVVe, as well as continued access to capital during the pre‑commercial phase.

NEWS

November 26, 2025 · 8:48 AM UTC

enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment

Read more

November 13, 2025 · 5:00 PM UTC

enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve

Read more

October 31, 2025 · 8:05 AM UTC

enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Read more

September 26, 2025 · 8:45 AM UTC

enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment

Read more